Good News
The UAE Ministry of Health and Prevention announced, in collaboration with the Department of Health – Abu Dhabi and Dubai Health Authority, the results of the on-going treatment for the anti-viral medicine ‘Sotrovimab’, which was being tested to treat mild to moderate Covid-19 cases among the other patients such as, adults, pregnant women and children below 12 years old, that are at high risk of developing severe symptoms.
About 52 per cent were aged 50 or above and almost all recipients had multiple comorbidities including obesity, cancer, cardiovascular disease and diabetes.
— مكتب أبوظبي الإعلامي (@admediaoffice) July 17, 2021
Read more: https://t.co/0SokhfhQgK
Between 30th June and 13 July 2021, Sotrovimab had been administered to 6,175 patients with COVID-19 in Abu Dhabi, and about 52% of the patients were aged 50 or above, who shared almost the same symptoms including multiple comorbidities, obesity, cancer, cardiovascular diseases and diabetes. The medication showed results of 97% of the recipients fully recovered, within 14 days.
More about the drug: Sotrovimab is a monoclonal antibody treatment delivered through intravenous therapy, and can be used to treat adults and children above the age of 12 who meet certain criteria and are at risk of progressing to a severe Covid-19 condition, as per protocols that have been developed by the National Scientific Committee.
Stay Safe & Get Vaxxed!
READ MORE:
Free Public Parking Has Been Announced for 3 Days in Sharjah & Dubai
READ MORE:
Here’s Your Travel Checklist For Summer 2021!
READ MORE:
Get Ready To Watch Perseids Meteor Shower in Sharjah!
